Home / 亚太区 / 中国 / 争议的解决
blue wineglass shattering on reflecting ground 的照片

争议的解决

如果您面临需要采取法律行动的问题,我们的团队将协助您分析风险、处理争议及寻找建设性的解决方案和处理方式。CMS专注于各行业的律师不仅是诉讼律师或仲裁专家,还是具有商业头脑的问题解决者。

如果您希望以诉讼或仲裁以外的方式解决争议,我们可引导您有策略地实现该目标。我们常在商业和国际争议的仲裁程序(包括投资仲裁)中担任顾问。我们的合伙人也经常担任仲裁人。

您面临的最大风险之一可能是有关公司不当行为指控的外部调查。我们的专家可为您提供全天候的支持,帮助应对刑事和监管机构发起的敏感调查,包括适时进行和解谈判。

根据中国法律,作为一家外资律师事务所,我们无权得代表客户在中国人民法院进行诉讼。对于此类诉讼业务,我们通常与内资律师事务所紧密合作,由他们直接代表客户进行诉讼。我们以同样的方式协助客户处理中国法院要求强制执行的判决与仲裁裁决。

凭借我们的全球经验和本土知识,我们可在州法院、仲裁法庭及其他争议解决中保护您的权益。我们在超过40个国家拥有400多名律师,可以跨越任何欧洲司法辖区处理您的争议,在涉外诉讼中获得司法协助,并处理国际判决及仲裁裁决的执行程序。

我们的奖项:

  • 中国领先争议解决:仲裁律师事务所(国际律师事务所),2021年,《钱伯斯》
  • 中国争议解决业务领先律师事务所–外国律师事务所,2020年,《法律500强》
  • 年度最佳争议解决团队,2015年,AI Dispute Awards

信息推送

12/12/2022
G­lo­ba­l Li­fe Scien­ce­s & Hea­lthca­re Fo­ru­m 2022: Fa­cing the o­ppo­r­tu­ni­tie­s...
Di­gi­ta­l a­dvan­ce­s an­d in­nova­tive the­ra­pie­s a­re pu­shing the boun­da­rie­s o­f hea­lth an­d the le­ga­l wo­r­ld ha­s to kee­p pa­ce Li­fe scien­ce­s a­re fi­zzing wi­th in­ge­nui­ty an­d in­nova­tion wi­th revo­lu­tio­na­r­y ge­ne an­d...
22/11/2022
G­lo­ba­l Li­fe Scien­ce­s & Hea­lthca­re Fo­ru­m 2022: Li­fe Scien­ce­s a­re rea­ping...
Di­gi­ta­l t­ran­sfo­r­ma­tion in li­fe scien­ce­s i­s c­rea­ting o­ppo­r­tu­ni­tie­s to coun­ter hea­lthca­re’s mo­st in­t­ra­cta­ble p­ro­ble­ms f­ro­m t­rea­ting ra­re di­sea­se­s to a­cce­le­ra­ting dia­g­no­sti­cs an­d re­du­cing t­rea­tmen­t ba­cklo­g­s...
28/07/2022
Eng­li­sh Hi­g­h Cou­r­t per­mi­ts servi­ce o­f cou­r­t p­ro­cee­ding­s by N­FT
Fo­r the fi­r­st ti­me ou­tsi­de the U­ni­te­d Sta­te­s an­d fo­r on­ly the se­con­d ti­me wo­r­ldwi­de,[1] a cou­r­t ha­s a­llo­we­d the servi­ce o­f p­ro­cee­ding­s via non-fungi­ble to­ken (N­FT).  The ju­dg­men­t o­f T­ro­wer­s J in the...
04/07/2022
Su­stai­na­ble Deve­lo­pmen­t Goa­ls an­d Rea­ctive Le­ga­l Li­mi­ta­tion­s Perva­de the...
On 24 Ju­ne 2022, the 53 Con­t­ra­cting Pa­r­tie­s o­f the E­ner­g­y Cha­r­ter T­rea­ty (E­CT), a ke­y mu­lti­la­te­ra­l t­rea­ty p­ro­te­cting c­ro­ss-bo­r­der e­ner­g­y inve­stmen­ts tha­t wa­s o­ri­gi­na­lly con­clu­de­d in 1991, rea­che­d a ten­ta­tive...
28/06/2022
Te­ch­no­lo­g­y T­ran­sfo­r­ma­tion: Ma­na­ging Ri­sks in a Changing Lan­dsca­pe
Changing te­ch, changing ri­sks
24/06/2022
Sto­ckho­lm A­r­bi­t­ra­tion T­ri­bu­na­l De­nie­s Ju­ri­sdi­ction over In­t­ra-EU Inve­stmen­t...
In a g­roun­db­rea­king a­wa­r­d, da­te­d 16 Ju­ne 2022, ma­de in G­reen Po­wer Pa­r­t­ner­s K/S an­d SCE So­la­r Don Be­ni­to A­PS v The King­do­m o­f Spain, a t­ri­bu­na­l con­sti­tu­te­d un­der the A­r­bi­t­ra­tion Ru­le­s o­f the A­r­bi­t­ra­tion...
20/06/2022
The U­ni­te­d Sta­te­s Su­p­re­me Cou­r­t Re­st­ri­cts Di­scover­y fo­r In­ter­na­tio­na­l A­r­bi­t­ra­tion­s
In a lan­dma­r­k de­ci­sion i­ssue­d on 13 Ju­ne 2022,[1] the U­S Su­p­re­me Cou­r­t (“SCO­TU­S”), A­me­ri­ca’s hi­g­he­st cou­r­t, ru­le­d tha­t the sco­pe o­f Se­ction 1782 o­f the U­ni­te­d Sta­te­s Co­de (“U.S.C.”) doe­s no­t...
07/06/2022
A­dver­se e­ffe­cts o­f d­ru­g­s an­d va­cci­ne­s in Chi­na
1. D­ru­g a­dver­se e­ffe­cts: kin­ds o­f re­spon­si­bi­li­ty 1.1 Whi­ch a­re the main kin­ds o­f re­spon­si­bi­li­ty (con­t­ra­ctua­l, in to­r­t, c­ri­mi­na­l) o­f the fo­llo­wing su­bje­cts wi­th re­spe­ct to a­dver­se d­ru­g­s rea­ction­s? A...
Comparable
01/06/2022
CMS Ne­xt
Wha­t’s ne­xt? In a wo­r­ld o­f ever-a­cce­le­ra­ting chan­ge, sta­ying a­hea­d o­f the cu­rve an­d k­no­wing wha­t’s ne­xt fo­r you­r bu­si­ne­ss o­r se­cto­r i­s e­ssen­tia­l.A­t CMS, we see ou­r­se­lve­s no­t on­ly a­s you­r le­ga­l a­dvi­ser­s bu­t a­lso a­s you­r bu­si­ne­ss pa­r­t­ner­s. We wo­r­k to­ge­ther wi­th you to no­t on­ly re­so­lve cu­r­ren­t i­ssue­s bu­t to an­ti­ci­pa­te fu­tu­re cha­llen­ge­s an­d in­nova­te to mee­t the­m.Wi­th ou­r la­te­st pu­bli­ca­tion, CMS Ne­xt, ou­r e­xper­ts wi­ll re­gu­la­r­ly o­ffer you in­si­g­hts in­to an­d f­re­sh per­spe­ctive­s on a ran­ge o­f i­ssue­s tha­t bu­si­ne­sse­s have to dea­l wi­th – f­ro­m E­SG a­gen­da­s to re­st­ru­ctu­ring a­fter the pan­de­mi­c o­r fa­cing the di­gi­ta­l t­ran­sfo­r­ma­tion. We wi­ll a­lso sha­re wi­th you mo­re a­bou­t the wo­r­k tha­t we a­re doing fo­r ou­r clien­ts, he­lping the­m in­nova­te, g­ro­w an­d mi­ti­ga­te ri­sk.To be a­ble to p­rovi­de you wi­th the be­st su­ppo­r­t, we i­mmer­se ou­r­se­lve­s in you­r wo­r­ld to un­der­stan­d you­r le­ga­l nee­ds an­d cha­llen­ge­s. Ho­wever, i­t i­s e­qua­lly i­mpo­r­tan­t tha­t you k­no­w who we a­re an­d ho­w we can wo­r­k wi­th you. So, we invi­te you to mee­t ou­r e­xper­ts an­d ca­tch a g­li­mpse o­f wha­t i­s ha­ppe­ning in­si­de CMS.En­jo­y rea­ding thi­s pu­bli­ca­tion, whi­ch we wi­ll u­pda­te re­gu­la­r­ly wi­th ne­w con­ten­t.CMS E­xe­cu­tive Tea­m
20/05/2022
A­men­de­d I­CSI­D Ru­le­s to en­ter in­to fo­r­ce on 1 Ju­ly 2022
On 21 Ma­r­ch 2022, the Me­mber Sta­te­s o­f the In­ter­na­tio­na­l Cen­t­re fo­r Se­ttle­men­t o­f Inve­stmen­t Di­spu­te­s (I­CSI­D) a­do­pte­d a co­mp­re­hen­sive se­t o­f a­men­dmen­ts to I­CSI­D a­r­bi­t­ra­tion an­d con­ci­lia­tion ru­le­s (“I­CSI­D...
22/04/2022
Do Chi­ne­se su­bsi­dia­rie­s o­f EU sha­re­ho­lder­s an­d EU na­tio­na­ls in Chi­na have...
Re­cen­tly the EU i­mpo­se­d a­ddi­tio­na­l san­ction­s on Ru­ssia an­d Ru­ssian co­mpa­nie­s an­d in­divi­dua­ls. Fo­r fo­rei­g­n inve­ste­d en­ter­p­ri­se­s wi­th EU sha­re­ho­lder­s an­d EU na­tio­na­ls in Chi­na, the que­stion­s a­ri­se­s whe­ther...
21/04/2022
欧盟股东及个人的中国子公司须遵守欧盟对俄罗斯实施的制裁吗?
请点击这里阅读全文。